Sort
10,766 grants matching “checkpoint inhibitor”
Mechanisms Governing Expansion of Embryonic Progenitor Cells (EPCs) in Metaplasia
$401,665Jason C Mills · Washington University · R01 · FY2020 · CA
Immune activation by necroptotic cell death
$401,522Andrew Atwell Oberst · University Of Washington · R01 · FY2023 · CA
Engineered Ensemble Nanoimmunotherapies for Cancer
$401,491Rohan Fernandes · George Washington University · R37 · FY2022 · CA
Mechanisms Governing Expansion of Embryonic Progenitor Cells (EPCs) inMetaplasia
$401,490Jason C Mills · Baylor College Of Medicine · R01 · FY2021 · CA
Exploiting WEE1/p53 synthetic lethality as a novel therapy in head and neck cancer
$401,486Bruce E Clurman · Fred Hutchinson Cancer Research Center · R01 · FY2020 · CA
Interplay between LINE-1 retrotransposons, condensins, and IFN
$401,222Michelle S Longworth · Cleveland Clinic Lerner Com-Cwru · R01 · FY2025 · GM
Core 1: Biospecimen and Data Management Core
$401,189John B Sunwoo · Stanford University · U54 · FY2019 · CA
PD-1 blockade with cryoablation and dendritic vaccine to treat lymphoma
$401,153Yi Lin · Mayo Clinic Rochester · R01 · FY2020 · CA
Analyzing DNA replication and damage vulnerability in IDH mutant glioma
$401,140Daniel P. Cahill · Massachusetts General Hospital · R01 · FY2025 · CA
Development of Novel Antibody Conjugates for Cancer Immunotherapy
$401,115Weiping Tang · University Of Wisconsin-Madison · R01 · FY2025 · CA
IL-6 and IL-6R genetic polymorphisms in immune-related adverse events caused by cancer immunotherapy
$401,115Mercedes R. Rincon · University Of Colorado Denver · R21 · FY2024 · CA
Interruption of cholesterol metabolism and replication stress response in cancer therapy
$401,115Junran Zhang · Ohio State University · R21 · FY2020 · CA
Study of the IL-33-driven immune cell organization underpinning responses to immune checkpoint blockade cancer therapy
$401,113Binfeng Lu · Hackensack University Medical Center · R01 · FY2025 · CA
Clinical Studies for Improving Survival Rates for Oral Cancer Patients in Low Resource Settings
$401,107Manijeh N Goldberg · Privo Technologies, Llc · R44 · FY2022 · CA
Protective role of Clec7a/dectin-1 in CNS autoimmunity
$401,063Mari L. Shinohara · Duke University · R01 · FY2021 · NS
Developmental Funds
$401,062C Kent Osborne · Baylor College Of Medicine · P30 · FY2021 · CA
Targeting leukemic stem cells in acute myeloid leukemia
$401,054Cheng-Kui Qu · Emory University · R01 · FY2024 · CA
Apoptosis in Postmitotic Cells: Increased Regulation and Novel Checkpoints
$401,018Mohanish Deshmukh · Univ Of North Carolina Chapel Hill · R01 · FY2009 · GM
Protective role of Clec7a/dectin-1 in CNS autoimmunity
$401,008Mari L. Shinohara · Duke University · R01 · FY2022 · NS
Mre11-Dependent DNA Damage Responses in Breast Cancer Pathogenesis
$400,986Gaorav P. Gupta · Univ Of North Carolina Chapel Hill · R37 · FY2024 · CA
Brain Tumor Immunotherapy
$400,968Mark Gilbert · Division Of Basic Sciences - Nci · ZIA · FY2019 · CA
Protective role of Clec7a/dectin-1 in CNS autoimmunity
$400,949Mari L. Shinohara · Duke University · R01 · FY2023 · NS
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$400,890Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2025 · CA
Shifting the balance between IFN-I and TGF-beta to improve cancer therapy
$400,890Mark W Jackson · Cleveland Clinic Lerner Com-Cwru · P01 · FY2022 · CA
Microbiome-Mediated Tumor Immunomodulation in a Pathomimetic Colorectal Cancer Chip
$400,890Hyun Jung Kim · Cleveland Clinic Lerner Com-Cwru · R33 · FY2025 · CA